Agreements reached under this partnership
Business Alliance- 1
Using the Company's AI drug discovery platform, aibVIS, the parties aim to create innovative small-molecule drugs targeting the mRNA of the PCSK9 gene selected by TORAY INDUSTRIES,INC. as a drug discovery target.
- 2
The Company and TORAY INDUSTRIES,INC. will jointly pursue drug discovery research from identification of the target structure on PCSK9 mRNA through to obtaining compounds that act on the structure and demonstrate pharmacological activity.
- 3
The Company will provide a broad range of platform technologies, including RNA structure analysis, screening of RNA-binding compounds, measurement of RNA substructures, three-dimensional structure analysis, and molecular design.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
As no milestone revenue or other payments will arise from this milestone achievement, there is no change to the earnings forecast for the fiscal year ending December 2026 announced on 12 February 2026.
| Item | Details |
|---|---|
| Name of alliance partner | TORAY INDUSTRIES,INC. |
| Alliance partner's location | Chuo-ku, Tokyo |
| Type of alliance | Business Alliance |
| Details of the alliance | Using the Company's AI drug discovery platform, aibVIS, the parties aim to create innovative small-molecule drugs targeting the mRNA of the PCSK9 gene selected by TORAY INDUSTRIES,INC. as a drug discovery target., The Company and TORAY INDUSTRIES,INC. will jointly pursue drug discovery research from identification of the target structure on PCSK9 mRNA through to obtaining compounds that act on the structure and demonstrate pharmacological activity., The Company will provide a broad range of platform technologies, including RNA structure analysis, screening of RNA-binding compounds, measurement of RNA substructures, three-dimensional structure analysis, and molecular design. |
| Contract Date | 28 July 2021 |
| Impact on Business Performance | As no milestone revenue or other payments will arise from this milestone achievement, there is no change to the earnings forecast for the fiscal year ending December 2026 announced on 12 February 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The research progressed in the joint drug discovery program, resulting in achievement of the important research milestone of obtaining hit compounds. As no income or other payments will arise from this milestone achievement, the earnings forecast remains unchanged.